Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurosurgical Endovascular Credentialing in Europe and the United Kingdom for the "Complete" Neurovascular Surgeon: The Time has Come.

Neurosurgery·2026
Same author

Recommendations for studying the safety, efficacy and durability of intracranial aneurysm devices.

European stroke journal·2026
Same author

European Stroke Organisation (ESO), European Association of Neurosurgical Societies (EANS) and European Society for Minimally Invasive Neurological Therapy (ESMINT) guideline on aneurysmal subarachnoid haemorrhage.

European stroke journal·2026
Same author

Vaccination of immunosuppressed patients.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same author

Hyperfractionated reirradiation and PD-1 blockade in recurrent squamous cell head and neck carcinomas with poor prognosis, results from the REPORT-trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab.

BMJ neurology open·2026

Related Experiment Video

Updated: Mar 1, 2026

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas
07:00

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

6.4K

Olfactory neuroblastoma: a single-center experience.

Marton König1,2, Terje Osnes3,4, Peter Jebsen5

  • 1Department of Neurosurgery, Oslo University Hospital-Rikshospitalet, PB4950 Nydalen, 0424, Oslo, Norway. m.s.s.konig@medisin.uio.no.

Neurosurgical Review
|May 26, 2017
PubMed
Summary

Craniofacial resection (CFR) with or without radiotherapy (XRT) offers excellent survival for olfactory neuroblastoma (ONB) patients when negative margins are achieved. Advanced disease and positive margins correlate with poor outcomes.

Keywords:
Craniofacial resectionEsthesioneuroblastomaMultidisciplinary approachMultimodal treatmentOlfactory neuroblastomaSurvival

More Related Videos

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
09:53

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

4.3K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.5K

Related Experiment Videos

Last Updated: Mar 1, 2026

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas
07:00

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

6.4K
Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
09:53

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

4.3K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.5K

Area of Science:

  • Oncology
  • Head and Neck Surgery
  • Pathology

Background:

  • Olfactory neuroblastoma (ONB) is an aggressive malignancy with a poor prognosis.
  • Despite its aggressive nature, ONB is potentially curable with appropriate management.
  • Evaluating treatment outcomes is crucial for optimizing patient care.

Purpose of the Study:

  • To assess the management outcomes for patients with olfactory neuroblastoma (ONB).
  • To identify prognostic factors influencing survival in ONB patients.
  • To evaluate the safety and efficacy of craniofacial resection (CFR) in ONB treatment.

Main Methods:

  • A retrospective analysis of 20 ONB patients treated between 1998 and 2016.
  • Data collected from prospective brain tumor databases and head and neck cancer registries.
  • Cases were re-examined by a dedicated head and neck pathologist; chart reviews supplemented data.

Main Results:

  • 100% survival at 10 years was observed with CFR and negative surgical margins.
  • Positive margins were associated with significantly poorer outcomes (survival <44 months).
  • Advanced disease (tumor size ≥40 mm, Kadish C/D, TNM IVa/IVb) and positive margins predicted dismal survival.

Conclusions:

  • Craniofacial resection (CFR), with or without adjuvant radiotherapy (XRT), is a safe and effective treatment for ONB.
  • Achieving negative surgical margins is a critical factor for long-term survival.
  • Negative margins, smaller tumor size (<40 mm), and earlier stages (Kadish A/B, TNM I-III) are independent predictors of favorable outcomes.